Sitaxsentan - Leo Pharma
Alternative Names: PAT-S03; TMB-003Latest Information Update: 30 Jul 2024
At a glance
- Originator Patagonia Pharmaceuticals
- Developer LEO Pharma; Trex Wind-down
- Class Antihypertensives; Benzodioxoles; Heart failure therapies; Isoxazoles; Small molecules; Sulfonamides; Thiophenes
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Lichen sclerosus et atrophicus
- Discontinued Scleroderma
Most Recent Events
- 29 Jul 2024 Preclinical development is ongoing for Lichen sclerosus et atrophicus in USA (Topical) (Timber Pharmaceuticals pipeline, July 2024)
- 29 Jul 2024 Discontinued - Preclinical for Scleroderma in USA (SC) prior to July 2024 (Timber Pharmaceuticals pipeline July 2024)
- 28 Feb 2024 No recent reports of development identified for preclinical development in Lichen sclerosus et atrophicus in USA (Topical)